Previous 10 |
First patient injected in phase I trial evaluating tumor-agnostic NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer This first injection expands evaluation of NBTXR3 to its seventh indication either as a single agent activ...
Nanobiotix's (NBTX) subsidiary Curadigm has submitted a research project involving its Nanoprimer technology which was selected for the Sanofi iTech Awards Program, which will provide an opportunity to establish proof of concept as a combination product that could expand the be...
Nanobiotix subsidiary, Curadigm, submitted a research project involving its Nanoprimer technology which was selected for the Sanofi iTech Awards Program, as a highly promising option to significantly improve gene therapy development Following this selection, Curadigm will en...
Positive first results from the complete dose-finding part of a phase Ib/II study of tumor-agnostic NBTXR3 (PEP503) activated by radiotherapy with concurrent chemotherapy for patients with rectal cancer show that intratumoral injection of the product candidate was feasible and it wa...
Nanobiotix (NBTX) announces positive first results from the complete phase Ib part of a phase Ib/II study evaluating NBTXR3 (PEP503) activated by radiotherapy with concurrent chemotherapy. Radiotherapy, chemotherapy and surgery are elements of the standard of care for patients with recta...
Nanobiotix (NBTX) plans tapping into its IPO proceeds to launch a global Phase 3 registration study of NBTXR3 in head and neck cancer in the U.S. this year. Shares began trading on Nasdaq in December last year.The company, will provide an update on its immuno-oncology Phase I basket...
Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021 Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 no...
Expectations are coming in for 2021. Despite the strong recent gains and record valuations, analysts and investors are expecting even more upside based on "the new normal". The IPO market has proven to be an extremely valuable indicator for future returns. Investors are clearly missin...
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...